We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes (EXPLORE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01192425
First Posted: September 1, 2010
Last Update Posted: September 1, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Alexion Pharmaceuticals
  Purpose
Examine red and white blood cells of PNH patients with bone marrow failure syndromes.

Condition
Hemoglobinuria

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: P06-001: (EX)Amination of (P)NH, by (L)Evel (O)f CD59 on (RE)d and White Blood Cells, in Bone Marrow Failure Syndromes

Resource links provided by NLM:


Further study details as provided by Alexion Pharmaceuticals:

Enrollment: 5580
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   10 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients at least 10 years of age with aplastic anemia, myelodyplastic syndromes or other bone marrow failure syndromes.
Criteria

Inclusion Criteria:

  • At least 10 years of age.
  • Has aplastic anemia, myelodysplastic syndromes or other bone marrow failure syndromes

Exclusion Criteria:

  • Has any condition that might interfere with the patient's participation
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Michael Bombara, Senior Director, Global Clinical Operations, Alexion Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01192425     History of Changes
Other Study ID Numbers: P06-001
First Submitted: August 30, 2010
First Posted: September 1, 2010
Last Update Posted: September 1, 2010
Last Verified: August 2010

Keywords provided by Alexion Pharmaceuticals:
PNH clone cells
Aplastic Anemia
AA
Myelodysplastic Syndromes
MDS
bone marrow failure syndromes
FLAER
Paroxysmal Nocturnal Hemoglobinuria

Additional relevant MeSH terms:
Syndrome
Hemoglobinuria
Hemoglobinuria, Paroxysmal
Pancytopenia
Disease
Pathologic Processes
Proteinuria
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Anemia, Hemolytic
Anemia
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases


To Top